ArticleEuropean radiology2021
Radiologic and clinical results of transarterial ethanol embolization for renal angiomyolipoma.
Article in European radiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 18 citations in OpenAlex.
- Complication Rates and Effectiveness of Renal Angiomyolipoma Embolisation: A Systematic Review and Meta-analysis.Cardiovascular and interventional radiology · 2026Pooled it
- Safety and efficacy of transcatheter arterial embolization in renal angiomyolipomas: a systematic review and meta-analysis.BMC nephrology · 2025Pooled it
- Embolic Agent Selection and Outcomes in Renal Angiomyolipoma Embolisation.Journal of medical imaging and radiation oncology · 2026Observational
- A Radiopaque and Thermoresponsive Nanogel-Based Pickering Emulsion for Permanent Arterial Embolization.ACS omega · 2026Article
- Predictors of Hemorrhage and Re-Intervention in Renal Angiomyolipoma Following Transcatheter Arterial Embolization.Journal of clinical medicine · 2025Article
- Enhancing procedural decision making with cone beam CT in renal artery embolization.Scientific reports · 2024Article
- The radiomics-clinical nomogram for predicting the response to initial superselective arterial embolization in renal angiomyolipoma, a preliminary study.Frontiers in oncology · 2024Article
- Fat-poor renal angiomyolipoma with prominent cystic degeneration: A case report and review of the literature.World journal of clinical cases · 2023Article
- Endovascular management of renal angiomyolipomas: Do coils have a benefit in terms of clinical success rates?Diagnostic and interventional radiology (Ankara, Turkey) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveWe sought to determine the efficacy and safety of selective arterial embolization for renal angiomyolipoma (AML) using ethanol alone or ethanol with additional embolic materials and to analyze the factors influencing safety and efficacy.
methodsOne hundred nineteen AMLs treated with embolization were included retrospectively during a 15-year period. Technical, radiologic, and clinical success were recorded and risk factor analysis was performed. Complications on follow-up images, post-embolization syndrome (PES), major complications, and changes in renal function were also evaluated.
resultsTechnical success was achieved in 106 of 119 tumors. Tumor size significantly decreased after treatment (reduction rate: 55%). Significant risk factors for tumor reduction included tumor enhancement on preprocedural CT and residual tumor staining. Radiologic success was achieved in 114 of 119 tumors (risk factor: residual tumor staining), and clinical success was achieved in 22 of 23 patients. Complications on follow-up images occurred in 40 of 119 tumors, and PES occurred in 53 of 104 patients. No major complications occurred. There were no cases of renal function impairment.
conclusionSelective transarterial embolization using ethanol alone or ethanol with additional embolic materials reduced AML size, alleviated symptoms, and can be performed safely without permanent impairment. KEY POINTS: • Percutaneous transarterial ethanol embolization reduces AML size and alleviates symptoms. • Embolization can be performed safely without permanent impairment of renal function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.